ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Piramal to produce bemcentinib for Norway’s BerGenBio

by Rick Mullin
December 12, 2019 | APPEARED IN VOLUME 97, ISSUE 48

09748-buscon14-bemcen.jpg

BerGenBio, a Norwegian biotech firm, has hired Piramal Pharma Solutions to produce bemcentinib, a medication in development to treat elderly patients with relapsed acute myeloid leukemia. Piramal says it will source intermediates from India, conduct pilot process development and active ingredient validation in North America, and do formulation work in Europe. Bemcentinib was designated a fast-track drug by the US Food and Drug Administration, the partners say.

X

Article:

This article has been sent to the following recipient:

Comments
ram (December 14, 2019 11:49 AM)
Nice one

Leave A Comment

*Required to comment